Dorothée Sémiond - Concepedia

Author

Dorothée Sémiond

Also Known As

D Sémiond, D. Semiond, D. Sémiond, Dorothee Semiond, Dorothée Semiond, Dorothée R. Sémiond, Dorothée Semiond, Dorothée Sémiond

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Sanofi (France)Sanofi (United States)Sanofi (Germany)AVEO Oncology (United States)Institut Jules Bordet

About

Dorothée Sémiond is an author at Sanofi (France) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	341
2	Natural Sciences	2	2	82
3	Biochemistry	2	2	82
4	Social Sciences	1	1	13
5	Cell Biology	1	1	53

Dorothée Sémiond

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors Alain C. Mita, Louis Denis, Eric K. Rowinsky, Clinical Cancer Research	2009	328
Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors Patricia Vrignaud, Dorothée Sémiond, Pascale Lejeune, Clinical Cancer Research	2013	221
Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and rats Salvatore Cisternino, Fanchon Bourasset, Yves Archimbaud, British Journal of Pharmacology	2003	112
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma Joseph Mıkhael, Paul G. Richardson, Saad Z. Usmani, Blood	2019	88
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer D. Rea, J. W. R. Nortier, W.W. ten Bokkel Huinink, Annals of Oncology MedicinePharmacologyPharmacokinetic StudyColorectal CancerPharmacotherapy	2005	79
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis Meletios Α. Dimopoulos, Xavier Leleu, Philippe Moreau, Leukemia	2020	70
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study Cristian Villanueva, Ahmad Awada, Mario Campone, European Journal of Cancer Taxane TreatmentOncologyPhase I/ii StudyMedicineBreast Cancer	2011	63
Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study Véronique Dièras, Alain Lortholary, Valérie Laurence, European Journal of Cancer MedicinePharmacologyPharmacokinetic StudyAdvanced Solid TumoursPharmacotherapy	2012	60
Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein George E. Durán, Volker Derdau, Dietmar Weitz, Cancer Chemotherapy and Pharmacology Chemical BiologyBiochemistryNatural SciencesMolecular BiologyCell Lines	2018	53
Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors Géraldine M. Ferron, Yang Dai, Dorothée Sémiond Cancer Chemotherapy and Pharmacology	2013	43

Page 1